Target intelligence / Profile preview

Erb-B2 receptor tyrosine kinase 2 mRNA 3' untranslated region poly-U sequence (ERBB2 3' UTR poly-U)

Target
ERBB2 3' UTR poly-U
Molecular classification
RNA, mRNA regulatory element
01

Overview

The Erb-B2 receptor tyrosine kinase 2 (ERBB2) mRNA 3' untranslated region (UTR) poly-U sequence is a critical post-transcriptional regulatory element located at the 3' end of the HER2 transcript. This uridine-rich sequence serves as a primary docking site for RNA-binding proteins (RBPs), most notably HuR (ELAVL1), which binds to the poly-U tract to enhance mRNA stability and facilitate efficient translation (Source: PubMed, PMID: 23503460). In many malignancies, including HER2-positive breast and gastric cancers, the stabilization of ERBB2 mRNA via this sequence leads to the pathological overexpression of the HER2 protein, driving uncontrolled cell proliferation and survival (Source: UniProt, P04626). Therapeutic interventions targeting this specific RNA sequence, such as antisense oligonucleotides (ASOs) or small molecules that disrupt RBP-mRNA interactions, aim to decrease HER2 protein levels by promoting mRNA decay (Source: Journal of Biological Chemistry). This target represents a novel approach to overcoming resistance to traditional HER2-targeted therapies like trastuzumab by addressing the source of protein production at the genetic message level.

Other names
HER2 mRNA 3' UTR U-rich elementERBB2 3' UTR regulatory elementERBB2 mRNA 3' UTR poly-uridine sequenceHER2 3' UTR URE
02

Mechanism of action

Disruption of mRNA-protein interactions (e.g., HuR binding) to promote mRNA degradation or inhibit translation of the ERBB2 transcript.

03

Biological functions

mRNA stability regulationTranslation regulationPost-transcriptional gene regulation
04

Disease associations

Breast cancerGastric cancerOvarian cancerLung adenocarcinoma
05

Safety considerations

Off-target binding to other U-rich mRNA elements in the transcriptomePotential for systemic toxicity associated with RNA-targeting delivery platformsComplexity of RNA secondary structure interference affecting drug accessibility
06

Interacting drugs

Antisense oligonucleotides (experimental)

2 more in the full profile.

07

Biomarkers

HER2 protein expression (IHC/FISH)ERBB2 mRNA levelsHuR (ELAVL1) expression levels

Beyond the preview

Go deeper on Erb-B2 receptor tyrosine kinase 2 mRNA 3' untranslated region poly-U sequence (ERBB2 3' UTR poly-U).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erb-B2 receptor tyrosine kinase 2 mRNA 3' untranslated region poly-U sequence (ERBB2 3' UTR poly-U).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call